Autoinflammatory Diseases and Immunodeficiencies Center, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetic and Maternal-Infant Sciences, University of Genoa, Genoa, Italy.
G Ital Dermatol Venereol. 2020 Oct;155(5):590-598. doi: 10.23736/S0392-0488.20.06709-7. Epub 2020 Jul 2.
Type I interferonopathies are a clinically heterogeneous group of inherited disorders of the innate immune system characterized by constitutive activation of the type I interferon signaling pathway. Cutaneous vasculopathy, lipodystrophy, interstitial lung disease and brain calcifications are the typical manifestations characterizing affected patients. The pathogenic mechanism commonly underlying these disorders is the abnormal activation of immune pathways involved in recognition of non-self-oligonucleotides. These natural defenses against virus consent humans to survive the infections. Target therapies capable of inhibiting type I interferon signaling pathway seem effective in these patients, albeit with possible incomplete responses and severe side effects.
I 型干扰素病是一组临床异质性的先天性免疫系统遗传疾病,其特征是 I 型干扰素信号通路的组成性激活。皮肤血管病变、脂肪营养不良、间质性肺病和脑钙化是特征性表现。这些疾病的共同发病机制通常是涉及识别非自身寡核苷酸的免疫途径的异常激活。这些针对病毒的天然防御使人类能够在感染中存活。能够抑制 I 型干扰素信号通路的靶向治疗似乎对这些患者有效,尽管可能存在不完全反应和严重的副作用。